ACP
AVEO

Acuta Capital Partners’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Acuta Capital Partners’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,200
Closed -$33K – 95
2017
Q4 		$33K Buy
+1,200
New +$37.3K 0.01% 74

Other funds holding AVEO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Acuta Capital Partners's AVEO Position: Q1 2018 in Review

Acuta Capital Partners sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2018, closing a stake of 12,434 shares — an estimated $347K sold.

Acuta Capital Partners first reported a position in AVEO in Q1 2015 and held it in 2 quarters. The position peaked at $861K in Q1 2015. 90 funds tracked by Wall St. Rank hold AVEO as of Q1 2018.

  • Acuta Capital Partners reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • Acuta Capital Partners sold 12,434 AVEO Pharmaceuticals, Inc. shares in Q1 2018, an estimated $347K.
  • Acuta Capital Partners first reported a position in AVEO Pharmaceuticals, Inc. in Q1 2015 and held it in 2 quarters.
  • Acuta Capital Partners's AVEO Pharmaceuticals, Inc. position peaked at $861K in Q1 2015.
  • 90 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2018.

Based on Acuta Capital Partners's 13F filing for Q1 2018, filed 15 May 2018.